Evidence map›Paper›PMID 22174819›Full record

ArticlePloS one2011

Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition.

Wei Guo, Shuhong Wu, Li Wang, Xiaoli Wei, Xiaoying Liu, Ji Wang, Zhimin Lu, Melinda Hollingshead, Bingliang Fang

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Design, synthesis, and evaluation of novelJournal of enzyme inhibition and medicinal chemistry · 2020
    Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Simultaneous determination and validation of oncrasin-266 and its metabolites by HPLC-MS/MS: Application to a pharmacokinetic study.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2016
    Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Wei GuoDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Shuhong Wu
Li Wang
Xiaoli Wei
Xiaoying Liu
Ji Wang
Zhimin Lu
Melinda Hollingshead
Bingliang Fang
The University of Texas MD Anderson Cancer Center · USNational Cancer Institute · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Novel CTD inhibitors with synthetic lethality to oncogenic Ras for cancer therapyR01CA124951 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FANG, BINGLIANG · 2010 to 2013
$1.2M
NCI NIH HHS CA-016672NCI NIH HHS N01 CO012400NCI NIH HHS N01-CO-12400NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA 092481NCI NIH HHS R01 CA 124951NCI NIH HHS R01 CA124951
6 · The paper itself

Abstract

backgroundTo optimize the antitumor activity of oncrasin-1, a small molecule identified through synthetic lethality screening on isogenic K-Ras mutant tumor cells, we developed several analogues and determined their antitumor activities. Here we investigated in vitro and in vivo antitumor activity of NSC-743380 (1-[(3-chlorophenyl) methyl]-1H-indole-3-methanol, oncrasin-72), one of most potent analogues of oncrasin-1. METHODOLOGY AND PRINCIPAL

findingsIn vitro antitumor activity was determined in NCI-60 cancer cell line panel using cell viability assay. In vivo antitumor activity was determined in parallel with NSC-741909 (oncrasin-60) in xenograft tumors established in nude mice from A498, a human renal cancer cell line. Changes in gene expression levels and signaling pathway activities upon treatment with NSC-743380 were analyzed in breast and renal cancer cells by Western blot analysis. Apoptosis was demonstrated by Western blot analysis and flow cytometric analysis. NSC-743380 is highly active against a subset of cancer cell lines derived from human lung, colon, ovary, kidney, and breast cancers. The 50% growth-inhibitory concentration (GI(50)) for eight of the most sensitive cell lines was ≤ 10 nM. In vivo study showed that NSC-743380 has a better safety profile and greater antitumor activity than NSC-741909. Treatment with NSC-743380 caused complete regression of A498 xenograft tumors in nude mice at the tested doses ranging from 67 mg/kg to 150 mg/kg. Mechanistic characterization revealed that NSC-743380 suppressed the phosphorylation of C-terminal domain of RNA polymerase II, induced JNK activation, inhibited JAK2/STAT3 phosphorylation and suppressed cyclin D1 expression in sensitive human cancer cells. Blocking JNK activation or overexpression of constitutively active STAT3 partially blocked NSC-743380-induced antitumor activity.

conclusionsNSC-743380 induces antitumor activity through modulation of functions in multiple cancer related pathways and could be a potential anticancer agent for some solid tumors.

Indexed as

AnimalsAntineoplastic AgentsApoptosisCell Line, TumorEnzyme ActivationFemaleHumansIndolesJNK Mitogen-Activated Protein KinasesMiceMice, NudeProtein Kinase InhibitorsRNA Polymerase IISignal TransductionSTAT3 Transcription FactorSubcutaneous Tissue1-((3-chlorophenyl)methyl)-1H-indole-3-carbinolAntineoplastic AgentsIndolesJNK Mitogen-Activated Protein Kinasesoncrasin-1Protein Kinase InhibitorsRNA Polymerase IISTAT3 Transcription Factor

Identifiers

PMID22174819
PMCPMC3236185
OpenAlexW1965532315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.